» Articles » PMID: 33650640

Role of Chemokines in Hepatocellular Carcinoma (Review)

Overview
Journal Oncol Rep
Specialty Oncology
Date 2021 Mar 2
PMID 33650640
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatocellular carcinoma (HCC) is a prevalent malignant tumor worldwide, with an unsatisfactory prognosis, although treatments are improving. One of the main challenges for the treatment of HCC is the prevention or management of recurrence and metastasis of HCC. It has been found that chemokines and their receptors serve a pivotal role in HCC progression. In the present review, the literature on the multifactorial roles of exosomes in HCC from PubMed, Cochrane library and Embase were obtained, with a specific focus on the functions and mechanisms of chemokines in HCC. To date, >50 chemokines have been found, which can be divided into four families: CXC, CX3C, CC and XC, according to the different positions of the conserved N‑terminal cysteine residues. Chemokines are involved in the inflammatory response, tumor immune response, proliferation, invasion and metastasis via modulation of various signaling pathways. Thus, chemokines and their receptors directly or indirectly shape the tumor cell microenvironment, and regulate the biological behavior of the tumor. In addition, the potential application of chemokines in chemotaxis of exosomes as drug vehicles is discussed. Exosomes containing chemokines or expressing receptors for chemokines may improve chemotaxis to HCC and may thus be exploited for targeted drug delivery.

Citing Articles

Ribosomal proteins in hepatocellular carcinoma: mysterious but promising.

Su Q, Sun H, Mei L, Yan Y, Ji H, Chang L Cell Biosci. 2024; 14(1):133.

PMID: 39487553 PMC: 11529329. DOI: 10.1186/s13578-024-01316-3.


A Novel Liver Cancer-Selective Histone Deacetylase Inhibitor Is Effective against Hepatocellular Carcinoma and Induces Durable Responses with Immunotherapy.

Wu B, Tapadar S, Ruan Z, Sun C, Arnold R, Johnston A ACS Pharmacol Transl Sci. 2024; 7(10):3155-3169.

PMID: 39416967 PMC: 11475281. DOI: 10.1021/acsptsci.4c00358.


CCL17, CCL22 and their receptor CCR4 in hematologic malignancies.

Zou S, Liu B, Feng Y Discov Oncol. 2024; 15(1):412.

PMID: 39240278 PMC: 11379839. DOI: 10.1007/s12672-024-01210-x.


CCL16 is a pro-tumor chemokine that recruits monocytes and macrophages to promote hepatocellular carcinoma progression.

Chi H, Lin Y, Wu Y, Chang C, Wu C, Yeh C Am J Cancer Res. 2024; 14(7):3600-3613.

PMID: 39113854 PMC: 11301285. DOI: 10.62347/VCTW6889.


The roles of cancer stem cell-derived secretory factors in shaping the immunosuppressive tumor microenvironment in hepatocellular carcinoma.

Muliawan G, Lee T Front Immunol. 2024; 15:1400112.

PMID: 38868769 PMC: 11167126. DOI: 10.3389/fimmu.2024.1400112.


References
1.
Li L, Xu L, Yan J, Zhen Z, Ji Y, Liu C . CXCR2-CXCL1 axis is correlated with neutrophil infiltration and predicts a poor prognosis in hepatocellular carcinoma. J Exp Clin Cancer Res. 2015; 34:129. PMC: 4621872. DOI: 10.1186/s13046-015-0247-1. View

2.
Liu Y, Yeh C, Lin K . Cancer Stem Cell Functions in Hepatocellular Carcinoma and Comprehensive Therapeutic Strategies. Cells. 2020; 9(6). PMC: 7349579. DOI: 10.3390/cells9061331. View

3.
Teng F, Tian W, Wang Y, Zhang Y, Guo F, Zhao J . Cancer-associated fibroblasts promote the progression of endometrial cancer via the SDF-1/CXCR4 axis. J Hematol Oncol. 2016; 9:8. PMC: 4744391. DOI: 10.1186/s13045-015-0231-4. View

4.
Han K, He X, Ma M, Guo X, Zhang X, Chen J . Inflammatory microenvironment and expression of chemokines in hepatocellular carcinoma. World J Gastroenterol. 2015; 21(16):4864-74. PMC: 4408458. DOI: 10.3748/wjg.v21.i16.4864. View

5.
Liu L, Zhang Z, Zheng B, Shi Y, Duan M, Ma L . CCL15 Recruits Suppressive Monocytes to Facilitate Immune Escape and Disease Progression in Hepatocellular Carcinoma. Hepatology. 2018; 69(1):143-159. DOI: 10.1002/hep.30134. View